Creative Planning Acquires 7,212 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Creative Planning grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 33.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,652 shares of the company’s stock after acquiring an additional 7,212 shares during the quarter. Creative Planning’s holdings in MaxCyte were worth $111,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of MXCT. Mirae Asset Global Investments Co. Ltd. acquired a new stake in MaxCyte during the 1st quarter worth approximately $174,000. Russell Investments Group Ltd. bought a new stake in MaxCyte in the 1st quarter valued at $28,000. US Bancorp DE boosted its stake in MaxCyte by 960.0% in the 1st quarter. US Bancorp DE now owns 95,852 shares of the company’s stock worth $402,000 after purchasing an additional 86,809 shares during the period. Blair William & Co. IL increased its holdings in MaxCyte by 7.3% during the 1st quarter. Blair William & Co. IL now owns 273,064 shares of the company’s stock worth $1,144,000 after purchasing an additional 18,501 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of MaxCyte by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company’s stock valued at $22,404,000 after purchasing an additional 65,004 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Stock Performance

NASDAQ:MXCT opened at $3.54 on Wednesday. The company has a market cap of $373.41 million, a PE ratio of -10.53 and a beta of 1.40. The stock has a 50-day simple moving average of $3.82 and a 200 day simple moving average of $4.18. MaxCyte, Inc. has a 52-week low of $3.23 and a 52-week high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period last year, the company earned ($0.11) earnings per share. On average, research analysts predict that MaxCyte, Inc. will post -0.43 earnings per share for the current fiscal year.

Insider Transactions at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the sale, the director now owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Stanley C. Erck sold 29,767 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total transaction of $118,174.99. Following the transaction, the director now directly owns 269,118 shares in the company, valued at approximately $1,068,398.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stanley C. Erck sold 21,607 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total transaction of $80,161.97. Following the completion of the sale, the director now owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,374 shares of company stock worth $233,797 in the last three months. Insiders own 3.00% of the company’s stock.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.